CASI Pharmaceuticals Inc. CASIF
0.13
(0.03)
(18.75%)
as of 25 Sep
- Market cap
- $12.4M
- P/E
- 0.0×
Follow CASIF
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 0.76 | 0.99 | 0.58 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (0.76) | (0.91) | (0.63) | |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | |
EV/Sales |
— | 2.54 | 2.23 | 1.56 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (0.60) | (0.74) | (0.61) | |
EV/FCF |
— | (0.59) | (0.73) | (0.60) | |
Quick Ratio |
0.11 | 0.20 | 0.19 | 0.32 | |
Current Ratio |
0.15 | 0.27 | 0.30 | 0.48 | |
Net Debt/EBITDA |
0.00 | (1.67) | (1.33) | (1.08) | |
Debt/Assets |
93.91% | 91.36% | 77.08% | 60.04% | |
Debt/Equity |
(0.34) | (0.63) | (0.66) | (0.92) | |
Asset Turnover |
0.00 | 0.52 | 0.61 | 0.77 | |
Operating CF/Net income |
— | 1.59 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (0.02) | — | — | |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 17.10% | 45.95% | 41.29% | |
Selling, General and Administrative Expense of Revenue |
— | 195.40% | 310.15% | 264.53% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
— | 41.35% | 0.00% | 0.00% | |
Graham Net Nets |
— | (3.14) | (1.54) | (1.82) | |
Graham Number |
— | 10.80 | 10.98 | 9.23 | |
Earnings Yield |
— | (303.53%) | (181.33%) | (244.92%) | |
Free Cash Flow Yield |
— | (568.54%) | (308.14%) | (448.66%) | |
Revenue per Share |
— | 0.39 | 0.19 | 0.27 | |
Operating CF per Share |
— | (1.12) | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | (1.12) | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.30 | 0.29 | 0.44 | |
Shareholders Equity per Share |
0.00 | (2.01) | (1.78) | (1.31) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | (2.01) | (1.78) | (1.31) | |
Free Cash Flow |
— | (20.78) | — | — | |
Working Capital |
(56.59) | (36.21) | (27.51) | (19.57) | |
Capital Expenditures |
— | (0.03) | — | — | |
Net Current Asset Value |
(69.31) | (49.47) | (41.14) | (33.35) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
— | (180.70%) | (353.92%) | (320.36%) | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.52 | 9.72 | 6.88 | 6.55 | |
Average Payables |
1.13 | 1.89 | 1.16 | 0.80 | |
Average Inventory |
3.00 | 3.43 | 7.77 | 9.01 | |
Average Assets |
30.94 | 39.66 | 44.04 | 41.24 | |
Average Common Equity |
(33.17) | (17.72) | (7.37) | (5.64) |
Columns are period end dates